Resokine

Drug Profile

Resokine

Alternative Names: aTyr 1920; HisRSN4 - aTyr Pharma; Histidyl-tRNA synthetase - aTyr Pharma; HRS (1-60) - aTyr Pharma; Resected-tRNA synthetase - aTyr Pharma; Resokine IV; Truncated-tRNA synthetase - aTyr Pharma

Latest Information Update: 08 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator aTyr Pharma
  • Class Amino acids peptides and proteins; Amino acyl-tRNA synthetases; Aminoacyltransferases; Biological proteins; Proteins
  • Mechanism of Action Histidine-tRNA ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Immunological disorders; Inflammatory bowel diseases

Most Recent Events

  • 21 May 2014 Adverse events data from a phase I trial in Immunological disorders released by aTyr
  • 21 May 2014 aTyr completes a phase I trial in Immunological disorders in European Union
  • 24 Feb 2014 Phase-I clinical trials in Immunological disorders (in volunteers) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top